A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599
This study is recruiting at 16 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Colorectal Carcinoma
- Pancreatic Adenocarcinoma
- Breast Cancer
- Other Solid Tumors
- Ovarian Cancer
- Myeloid Neoplasms (AML/MDS)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Research Site · Gilbert, AZ
California · 4
- Research Site · Duarte, CA
- Research Site · Los Angeles, CA
- Research Site · Newport Beach, CA
- Research Site · Santa Monica, CA
Florida · 1
- Research Site · Jacksonville, FL
Massachusetts · 2
- Research Site · Boston, MA
- Research Site · Boston, MA
New Jersey · 1
- Research Site · New Brunswick, NJ
New York · 1
- Research Site · New York, NY
Oregon · 1
- Research Site · Portland, OR
Pennsylvania · 1
- Research Site · Pittsburgh, PA
Tennessee · 1
- Research Site · Nashville, TN
Texas · 2
- Research Site · Houston, TX
- Research Site · Round Rock, TX
Wisconsin · 1
- Research Site · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.